481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2016-12, Vol.27 (suppl_9) |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | suppl_9 |
| container_start_page | |
| container_title | Annals of oncology |
| container_volume | 27 |
| creator | Nakagawa, K. Yang, J.C-H. Park, K. Ohe, Y. Wu, Y-L. Gainor, J. Blackwood-Chirchir, A. Yang, R. Chang, I-F. Mok, T. |
| description | |
| doi_str_mv | 10.1093/annonc/mdw594.045 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdw594_045</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1093_annonc_mdw594_045</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1335-609e4278486de08517a9ff164c1b178d542281ccae7be0b0a1be2cbd283c2eaf3</originalsourceid><addsrcrecordid>eNpVkctv00AQxg0qEqFw4cZtjkTC7b78WG6V1Zao4SEIXK31ehwvtdfW7iZR_ns2TS9c5qHR95sZfUnygZIrSiS_VtZOVl-P7SGT4oqI7GWyoFku05IIepEsiGQ8LTIuXidvvP9LCMklk4sX70VJN-YHVD3qx1EFhIKxz3ADc688AofgjBpg6sCa_TTsRtXAwYQedI_jFHp0aj7C5MDMZjDj03zv_58aCzibFt0YSVs3HaK8UzpElUON86n4eHt_93OZjruggpnsJ9gUknxNLW5jv0fwQW0RVn_gLNo5hzZA_Dn1kTqAxhiGnd2CVlZjBH77Va2rJaguxO5Eh3B0kzcW4dHY03PG9qYxT9s3D6slPN_7NnnVqcHju-d8mfy-u91UX9L19_tVdbNONeU8S3MiUbCiFGXeIikzWijZdTQXmja0KNtMMFZSrRUWDZKGKNog003LSq4Zqo5fJvTM1fEs77CrZ2dG5Y41JfXJ1Ppsan02tY6m8n_2rZqY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Nakagawa, K. ; Yang, J.C-H. ; Park, K. ; Ohe, Y. ; Wu, Y-L. ; Gainor, J. ; Blackwood-Chirchir, A. ; Yang, R. ; Chang, I-F. ; Mok, T.</creator><creatorcontrib>Nakagawa, K. ; Yang, J.C-H. ; Park, K. ; Ohe, Y. ; Wu, Y-L. ; Gainor, J. ; Blackwood-Chirchir, A. ; Yang, R. ; Chang, I-F. ; Mok, T.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdw594.045</identifier><language>eng</language><ispartof>Annals of oncology, 2016-12, Vol.27 (suppl_9)</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1335-609e4278486de08517a9ff164c1b178d542281ccae7be0b0a1be2cbd283c2eaf3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Nakagawa, K.</creatorcontrib><creatorcontrib>Yang, J.C-H.</creatorcontrib><creatorcontrib>Park, K.</creatorcontrib><creatorcontrib>Ohe, Y.</creatorcontrib><creatorcontrib>Wu, Y-L.</creatorcontrib><creatorcontrib>Gainor, J.</creatorcontrib><creatorcontrib>Blackwood-Chirchir, A.</creatorcontrib><creatorcontrib>Yang, R.</creatorcontrib><creatorcontrib>Chang, I-F.</creatorcontrib><creatorcontrib>Mok, T.</creatorcontrib><title>481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpVkctv00AQxg0qEqFw4cZtjkTC7b78WG6V1Zao4SEIXK31ehwvtdfW7iZR_ns2TS9c5qHR95sZfUnygZIrSiS_VtZOVl-P7SGT4oqI7GWyoFku05IIepEsiGQ8LTIuXidvvP9LCMklk4sX70VJN-YHVD3qx1EFhIKxz3ADc688AofgjBpg6sCa_TTsRtXAwYQedI_jFHp0aj7C5MDMZjDj03zv_58aCzibFt0YSVs3HaK8UzpElUON86n4eHt_93OZjruggpnsJ9gUknxNLW5jv0fwQW0RVn_gLNo5hzZA_Dn1kTqAxhiGnd2CVlZjBH77Va2rJaguxO5Eh3B0kzcW4dHY03PG9qYxT9s3D6slPN_7NnnVqcHju-d8mfy-u91UX9L19_tVdbNONeU8S3MiUbCiFGXeIikzWijZdTQXmja0KNtMMFZSrRUWDZKGKNog003LSq4Zqo5fJvTM1fEs77CrZ2dG5Y41JfXJ1Ppsan02tY6m8n_2rZqY</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Nakagawa, K.</creator><creator>Yang, J.C-H.</creator><creator>Park, K.</creator><creator>Ohe, Y.</creator><creator>Wu, Y-L.</creator><creator>Gainor, J.</creator><creator>Blackwood-Chirchir, A.</creator><creator>Yang, R.</creator><creator>Chang, I-F.</creator><creator>Mok, T.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20161201</creationdate><title>481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy</title><author>Nakagawa, K. ; Yang, J.C-H. ; Park, K. ; Ohe, Y. ; Wu, Y-L. ; Gainor, J. ; Blackwood-Chirchir, A. ; Yang, R. ; Chang, I-F. ; Mok, T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1335-609e4278486de08517a9ff164c1b178d542281ccae7be0b0a1be2cbd283c2eaf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakagawa, K.</creatorcontrib><creatorcontrib>Yang, J.C-H.</creatorcontrib><creatorcontrib>Park, K.</creatorcontrib><creatorcontrib>Ohe, Y.</creatorcontrib><creatorcontrib>Wu, Y-L.</creatorcontrib><creatorcontrib>Gainor, J.</creatorcontrib><creatorcontrib>Blackwood-Chirchir, A.</creatorcontrib><creatorcontrib>Yang, R.</creatorcontrib><creatorcontrib>Chang, I-F.</creatorcontrib><creatorcontrib>Mok, T.</creatorcontrib><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakagawa, K.</au><au>Yang, J.C-H.</au><au>Park, K.</au><au>Ohe, Y.</au><au>Wu, Y-L.</au><au>Gainor, J.</au><au>Blackwood-Chirchir, A.</au><au>Yang, R.</au><au>Chang, I-F.</au><au>Mok, T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy</atitle><jtitle>Annals of oncology</jtitle><date>2016-12-01</date><risdate>2016</risdate><volume>27</volume><issue>suppl_9</issue><issn>0923-7534</issn><eissn>1569-8041</eissn><doi>10.1093/annonc/mdw594.045</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2016-12, Vol.27 (suppl_9) |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdw594_045 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | 481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T08%3A33%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=481TiP%20Checkmate%20722:%20A%20phase%203%20trial%20of%20nivolumab%20with%20chemotherapy%20or%20ipilimumab%20vs%20chemotherapy%20in%20epidermal%20growth%20factor%20receptor%20(EGFR)-mutation,%20T790M-negative%20stage%20IV%20or%20recurrent%20non-small%20cell%20lung%20cancer%20(NSCLC)%20after%20EGFR%20tyrosine%20kinase%20inhibitor%20(TKI)%20therapy&rft.jtitle=Annals%20of%20oncology&rft.au=Nakagawa,%20K.&rft.date=2016-12-01&rft.volume=27&rft.issue=suppl_9&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdw594.045&rft_dat=%3Ccrossref%3E10_1093_annonc_mdw594_045%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |